Aeterna Zentaris, Inc. (AEZS) Names Dr. Richard Sachse As New Chief Scientific Officer
Small cap
Seeking Alpha Analyst Since 2010
Aeterna Zentaris announced earlier today the recruitment of Richard Sachse, MD, PhD, to the position of Senior Vice President, Chief Scientific Officer. Prior to joining Aeterna Zentaris, Dr. Sachse sat as Vice President, Head of Global Translational Medicine, at Boehringer Ingelheim.
"We are very proud to welcome Dr. Sachse to our leadership team. As CSO, he will be responsible for all areas of our global research and development activities, while also serving on the corporate Operating Committee. In developing his industry career, Dr. Sachse has held increasingly responsible positions with several leading pharmaceutical companies, including Bayer, Schwarz Pharma, UCB and Boehringer Ingelheim, overseeing major drug development programs in a variety of different therapeutic areas, including oncology and endocrinology," stated President and CEO of Aeterna Zentaris, David Dodd.
Dr. Sachse commented in response, "I am delighted to get the opportunity to become part of Aeterna Zentaris' team and very much looking forward to contribute in advancing the Company's portfolio pipeline along the value chain. I believe that the combination of Aeterna Zentaris' highly qualified and motivated personnel, together with its strong scientific platform, holds much promise for the future success of our projects."
Dr. Sachse earned a degree in medicine from the Friedrich-Alexander-University Erlangen in Germany, as well as board certification in Clinical Pharmacology. With over 20 years of experience as a physician and scientist, he holds extensive expertise in a variety of different therapeutic areas, including oncology and endocrinology. In addition to registration studies, he is specifically experienced in the design and implementation of translational programs to bridge research programs to the clinic, as well as in the design and implementation of clinical pharmacology programs, including all required profiling studies and activities which enable successful registration of products at an international level.
From 1996 to 2000, Dr. Sachse held the role of International Project Leader at the Bayer AG Institute for Clinical Pharmacology, and Principal Investigator at the Bayer Clinical Pharmacology Unit. While there he implemented innovative exploratory development tools, including biomarkers, which are used to demonstrate early Proof of Concept. From 2001 to 2006, he held a number of different management roles within early and late phase clinical development programs, including responsibilities for completed Phase 3 programs leading to successful NDA/MAA submissions. In 2007, he became Senior Director, Head of Experimental Medicine, at UCB in Belgium after a merger. It was here that he managed the implementation of novel biomarkers in clinical development in order to provide data supporting identification of appropriate target indication and target population.
For more information, please visit aezsinc.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.